减剂量深度学习重建用于肝脏转移瘤腹部CT
这项前瞻性研究纳入51例活检证实的结直肠癌肝转移患者,在同一次屏气下分别行标准剂量和减剂量门静脉期腹部CT,比较标准剂量滤波反投影与减剂量深度学习图像重建对肝转移瘤的检出和图像质量。减剂量CT容积CT剂量指数较标准剂量降低65.1%,减剂量DLIR主观图像质量更优且转移瘤对比噪声比更高,但≤0.5 cm病灶检出率、病灶准确性和阅片者信心均较低。
要点
- 减剂量DLIR在容积CT剂量指数降低65.1%时主观图像质量优于标准剂量FBP(P < .001)。
- ≤0.5 cm病灶检出:标准剂量FBP 96.9%(63/65)vs 减剂量DLIR 72.3%(47/65)。
- 病灶准确性:标准剂量FBP 80.1%(129/161)vs 减剂量DLIR 67.1%(108/161)(P = .01)。
核心结论
- 减剂量DLIR在辐射剂量降低65%时改善了CT图像质量并保持对大于0.5 cm肝脏病灶的检出,但整体病灶表征和阅片者信心劣于标准剂量FBP。
研究设计与样本
- 前瞻性、健康保险可携性与责任法案合规研究,2019年9月至2021年4月,51例活检证实的结直肠癌肝转移患者在同一次屏气下行标准剂量和减剂量门静脉期腹部CT,由3名放射科医师在标准剂量FBP和减剂量DLIR上检出和表征病灶。
关键影像表现/征象
- 减剂量DLIR主观图像质量优于标准剂量FBP(P < .001)。
- 肝转移瘤平均对比噪声比:减剂量DLIR 3.9 ± 1.7 vs 标准剂量FBP 3.5 ± 1.4(P < .001)。
- 减剂量条件下阅片者病灶信心较低(P < .001)。
诊断标准与关键数值
- ≤0.5 cm病灶检出率:标准剂量FBP 96.9%(95%CI:89.3,99.6;63/65)vs 减剂量DLIR 72.3%(95%CI:59.8,82.7;47/65)。
- 病灶准确性:标准剂量FBP 80.1%(95%CI:73.1,86.0;129/161)vs 减剂量DLIR 67.1%(95%CI:59.3,74.3;108/161)(P = .01)。
- 共识别161个病灶(127个转移瘤、34个良性病灶),平均大小0.7 cm ± 0.3。
临床应用与阅片要点
- 减剂量DLIR在辐射剂量降低65.1%时保持对大于0.5 cm肝脏病灶的检出,但≤0.5 cm病灶检出率低于标准剂量FBP。
- 减剂量DLIR整体病灶表征和阅片者信心低于标准剂量FBP。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Assessment of liver lesions is constrained as CT radiation doses are lowered; evidence suggests deep learning reconstructions mitigate such effects. Purpose To evaluate liver metastases and image quality between reduced-dose deep learning image reconstruction (DLIR) and standard-dose filtered back projection (FBP) contrast-enhanced abdominal CT. Materials and Methods In this prospective Health Insurance Portability and Accountability Act-compliant study (September 2019 through April 2021), participants with biopsy-proven colorectal cancer and liver metastases at baseline CT underwent standard-dose and reduced-dose portal venous abdominal CT in the same breath hold. Three radiologists detected and characterized lesions at standard-dose FBP and reduced-dose DLIR, reported confidence, and scored image quality. Contrast-to-noise ratios for liver metastases were recorded. Summary statistics were reported, and a generalized linear mixed model was used. Results Fifty-one participants (mean age ± standard deviation, 57 years ± 13; 31 men) were evaluated. The mean volume CT dose index was 65.1% lower with reduced-dose CT (12.2 mGy) than with standard-dose CT (34.9 mGy). A total of 161 lesions (127 metastases, 34 benign lesions) with a mean size of 0.7 cm ± 0.3 were identified. Subjective image quality of reduced-dose DLIR was superior to that of standard-dose FBP (P < .001). The mean contrast-to-noise ratio for liver metastases of reduced-dose DLIR (3.9 ± 1.7) was higher than that of standard-dose FBP (3.5 ± 1.4) (P < .001). Differences in detection were identified only for lesions 0.5 cm or smaller: 63 of 65 lesions detected with standard-dose FBP (96.9%; 95% CI: 89.3, 99.6) and 47 lesions with reduced-dose DLIR (72.3%; 95% CI: 59.8, 82.7). Lesion accuracy with standard-dose FBP and reduced-dose DLIR was 80.1% (95% CI: 73.1, 86.0; 129 of 161 lesions) and 67.1% (95% CI: 59.3, 74.3; 108 of 161 lesions), respectively (P = .01). Lower lesion confidence was reported with a reduced dose (P < .001). Conclusion Deep learning image reconstruction (DLIR) improved CT image quality at 65% radiation dose reduction while preserving detection of liver lesions larger than 0.5 cm. Reduced-dose DLIR demonstrated overall inferior characterization of liver lesions and reader confidence. Clinical trial registration no. NCT03151564 © RSNA, 2022 Online supplemental material is available for this article.
引用
- Jensen, Gupta, Saleh, et al. Reduced-Dose Deep Learning Reconstruction for Abdominal CT of Liver Metastases. Radiology. 2022. PMID: 35014900. doi:10.1148/radiol.211838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。